ZOLADEX 3.6 mg, implant in a pre-filled syringe for subcutaneous use syringe
Active ingredients: Goserelin acetate, Goserelin
Commercialized according to BDPMDispensing in France: Prescription only
Implantsyringesous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ZOLADEX 3,6 mg, implant en seringue préremplie pour voie sous-cutanée
- Pharmaceutical form
- implant
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) polystyrène polyéthylène de 3,6 mg
- Marketing authorisation holder
- ASTRAZENECA
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 Nov 1988
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67037162CIP73293267CIP133400932932672Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| GOSÉRÉLINE (ACÉTATE DE)implant | — | SA |
| GOSÉRÉLINE BASEimplant | 3,6 mg · un implant | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.